Novo Nordisk strikes deal with French Biocorp to develop add-on device for insulin pen
French company Biocorp has signed a deal with Novo Nordisk concerning development and potential distribution of a so-called "smart add-on device" to Novo's pre-filled insulin pen Flextouch.
.jpg)
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Novo Nordisk continues to raise arms on the digital diabetes front. The French company Biocorp, which also collaborates with other pharmaceutical giants, informs that it has entered into an agreement with the Danish pharmaceutical company about the development and possible distribution of a "smart add-on device" to the pre-filled insulin pen Flextouch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk launches smart insulin pen in Denmark
For subscribers
